Table 2 Nestin and CD133 expression in human gliomas tissues with different clinical grading
Clinical Grading | NO. | Nestin (n, %) | CD133 (n, %) | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | 0 | 1+~2+ | 3 | 0 | 1+~2+ | 3 |
Low-grade tumors | 56 | 16 (28.6) | 32 (57.1) | 8(14.3) | 20 (37.1) | 27 (48.2) | 9(16.1) |
Astrocytoma | 18 | 7 (38.8) | 11 (61.1) | 0 (0) | 9 (50.0) | 9 (50.0) | 0 (0) |
Ependymoma | 15 | 6 (40.0) | 8 (53.3) | 1 (6.7) | 7 (46.7) | 7 (46.7) | 1 (6.7) |
Oligodendroglioma | 11 | 2 (18.2) | 8 (72.7) | 1 (9.1) | 3 (27.3) | 7 (63.6) | 1 (9.1) |
Oligodendroastrocytoma | 4 | 1 (25.0) | 1 (25.0) | 2 (50.0) | 1 (25.0) | 1 (25.0) | 2 (50.0) |
Pilocytic astrocytoma | 8 | 0 (0) | 4 (50.0) | 4 (50.0) | 0 (0) | 3 (37.5) | 5 (62.5) |
High-grade tumors | 69 | 6(8.7) | 36 (52.2) | 27 (39.1) | 7(10.1) | 37 (53.6) | 25 (36.2) |
GBM | 48 | 4 (8.3) | 28 (58.3) | 16 (33.3) | 5 (10.4) | 29 (60.4) | 14 (29.2) |
Anaplastic astrocytoma | 11 | 2 (18.2) | 6 (54.5) | 3 (27.3) | 2 (18.2) | 7 (63.6) | 2 (18.2) |
Malignant oligodendroglioma | 6 | 0 (0) | 1 (16.7) | 5 (83.3) | 0 (0) | 1 (16.7) | 5 (83.3) |
Malignant ependymoma | 4 | 0 (0) | 1 (25.0) | 3 (75.0) | 0 (0) | 0 (0) | 4 (100.0) |